Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine Target-Controlled Infusion System Accuracy Study
ChiCTR2100045701Phase 4Recruiting
- Sponsor
- Peking University Shenzhen Hospital
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of dexmedetomidine (2 arms), sponsored by Peking University Shenzhen Hospital. Primary endpoints: Effect chamber transport rate constant (Ke0) and System execution error. Started May 2021; status: recruiting.
02
Drugs
dexmedetomidine
Beyond the preview
Go deeper on ChiCTR2100045701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045701.